CANbridge Pharmaceuticals (1228.HK) In-Depth Fundamental Analysis Report

Based on collected data and market information, I will conduct an in-depth analysis of the stock price performance and fundamental support of CANbridge Pharmaceuticals Inc. (1228.HK).

According to actual market data, CANbridge Pharmaceuticals’ stock price indeed experienced a significant increase in 2025. As shown in the company overview data [0]:

Time Period	Performance
6-month return	+555.07%
1-year return	+1586.57%
Estimated year-start price	~HK$0.14-HK$0.15
Year-end price	~HK$2.55-HK$2.60

From a technical analysis perspective, although the annual return did not reach the market-rumored 1824%, an annual return of over 1500% is still extremely rare in the Hong Kong stock market.

Based on the latest quarterly financial data [0]:

Profitability Indicator	Value	Assessment
Net Profit Margin	-217.58%	Severe Losses
Operating Profit Margin	-260.76%	Sustained Cash Burn
ROE	30.81%	Distorted Book Value

: The company is currently in the early commercialization stage with a revenue scale of approximately USD 24.38 million, which is not yet sufficient to cover operating costs. A negative net profit margin indicates that the company is still in the “cash burn” phase and is far from its profit target.

Liquidity indicators show high financial risk [0]:

Liquidity Indicator	Value	Industry Healthy Level
Current Ratio	0.09	Ideal >1.5
Quick Ratio	0.04	Ideal >1.0
P/B Ratio	-2.11	Insolvent

: A current ratio of only 0.09 means the company has extremely weak short-term solvency, with almost no sufficient current assets to cover short-term liabilities. This is a high-risk level in the biopharmaceutical industry.

Based on calculations from professional valuation models [0]:

Scenario	Intrinsic Value	Comparison with Current Price
Conservative	-$169.68	-7608%
Neutral	-$578.63	-25703%
Optimistic	$5,424.39	+239917%

: Two of the three scenarios show negative values, indicating that based on the traditional discounted cash flow model, the company’s intrinsic value is negative. Only under extremely optimistic assumptions (66% revenue growth, EBITDA Margin -2423%) can the current valuation be supported. This valuation structure reflects huge disagreements among market participants regarding the company’s future prospects.

CANbridge Pharmaceuticals’ core business focuses on [1]:

1. Nerlynx (Neratinib)
   : Adjuvant therapy drug for breast cancer, already commercialized in the Chinese market
2. Rare Disease Pipeline
   : Multiple investigational drugs for rare diseases
3. Oncology Pipeline
   : R&D layout for cancer treatment drugs

Financial analysis shows the company adopts relatively aggressive accounting policies [0]:

• Low depreciation/capital expenditure ratio
• Limited upside potential for earnings
• Investors need to be cautious about the quality of reported earnings

1. Biopharmaceutical Industry Characteristics
   : Biotech companies usually rely on pipeline valuation before product commercialization, rather than current earnings
2. Market Sentiment Driven
   : Overall valuation restructuring of the Hong Kong biopharmaceutical sector in 2025
3. Product Volume Growth Expectations
   : Expected sales growth of core products like Nerlynx
4. Pipeline Value Reassessment
   : Clinical progress of investigational drugs may boost market confidence

1. Disconnect from Fundamentals
   : Revenue of only ~USD 24 million is insufficient to support a market capitalization of nearly USD 1 billion (current ~USD 960 million)
2. Liquidity Crisis
   : A current ratio of 0.09 indicates the company may face severe capital pressure
3. Sustained Losses
   : No clear profit timeline, with continuous negative cash flow
4. Valuation Model Failure
   : DCF valuation shows negative intrinsic value; current price relies entirely on market sentiment

Risk Type	Risk Level	Description
Liquidity Risk	Extremely High	Current ratio of only 0.09, solvency in doubt
Valuation Risk	Extremely High	Stock price is seriously disconnected from fundamentals
Business Risk	Medium-High	Commercialization capability yet to be verified
Market Risk	High	Highly volatile, easily affected by market sentiment

: CANbridge Pharmaceuticals’ 2025 stock price increase lacks solid fundamental support. The over 1500% increase is seriously disconnected from the company’s current financial situation— the company is still in a state of severe losses, with limited revenue scale and extremely high liquidity risk.

: The current stock price reflects more market optimism about future prospects (pipeline value, product volume growth) rather than current performance support. This valuation structure is based on highly uncertain assumptions; once market sentiment shifts or clinical trial results fail to meet expectations, the stock price may face sharp adjustments.

: Investors are advised to remain highly cautious and focus on:

1. Subsequent product commercialization sales data
2. Cash flow status and financing capabilities
3. Clinical trial progress of investigational drugs
4. Management’s capital allocation strategy

For value investors, the current valuation level does not have an attractive risk-reward ratio; for highly risk-tolerant speculators, they need to closely monitor fundamental changes and strictly set stop-loss levels.

---

[0] Jinling AI Financial Database - CANbridge Pharmaceuticals (1228.HK) Company Overview and Financial Analysis Data

[1] Bloomberg - Canbridge Pharmaceuticals Inc. Company Profile (https://www.bloomberg.com/profile/company/1228:HK)